DR-237 A computational framework for precision medicine of hereditary melanoma cancer

The overall objective of our study is to assess if melanoma with a specific DNA mutation (in the CDKN2A gene) may be more sensitive to certain treatments. In order to identify therapeutic vulnerabilities it is essential to obtain a comprehensive picture of the DNA alterations and RNA expression levels in the tumors. The combined DNA and RNA data of patients melanoma tumours, in conjunction with results from our analyses performed on melanoma cells, can be used to generate a computational model of melanoma with CDKN2A mutation, possibly allowing us to predict how treatment of melanoma with this mutation can be improved.

Remco van Doorn, Leiden University Medical Center, The Netherlands